Skip to main content
Premium Trial:

Request an Annual Quote

Cambridge Epigenetix Raises $88M in Series D Funding Round

NEW YORK – Cambridge Epigenetix said on Tuesday that it has raised $88 million in a Series D financing round.

Singapore's Temasek led the round, joined by new investors, including Third Point, and existing investors, including GV, New Science Ventures, Ahren Innovation Capital, and Sequoia.

The Cambridge, UK-based company said it would use the proceeds to commercialize its methylation sequencing technology. The firm's product detects methylated cytosine as well as the four DNA bases. The firm said it expects to begin selling kits and software in early 2022. 

"Our sequencing technology works with all sequencers and enhances their accuracy as opposed to replacing or competing with them," Shankar Balasubramanian, founder of Cambridge Epigenetix, said in a statement. "Further, our technology has the potential to dramatically reduce the cost of genome sequencing, as the low sample requirement and streamlined workflow facilitate its cost-effectiveness and ease of use without sacrificing accuracy." 

The round brings the total amount of fundraising for Cambridge Epigenetix to around $146 million. The firm raised $21 million in 2016.

The firm added that it is working on a "six-letter" kit.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.